Methods to individualize combination therapy
    14.
    发明申请
    Methods to individualize combination therapy 审中-公开
    个性化联合治疗方法

    公开(公告)号:US20060228694A1

    公开(公告)日:2006-10-12

    申请号:US10551374

    申请日:2004-04-02

    IPC分类号: A61K38/17 C12Q1/00 C12Q1/68

    摘要: Compositions which comprise delivery vehicles having stably associated therewith predetermined, patient-specific combinations of two or more agents, such as antineoplastic agents, are useful in achieving optimal therapeutic effects on a patient-by-patient basis when combinations of drugs are administered.

    摘要翻译: 包含递送载体的组合物,当两种或更多种药物如抗肿瘤药物的预定的患者特异性组合具有稳定相关性时,可用于在施用药物组合时实现逐个患者的最佳治疗效果。

    D and L etherlipid stereoisomers and liposomes
    20.
    发明授权
    D and L etherlipid stereoisomers and liposomes 失效
    D和L类醚脂立体异构体和脂质体

    公开(公告)号:US06667053B1

    公开(公告)日:2003-12-23

    申请号:US09540050

    申请日:2000-03-31

    IPC分类号: A61K9133

    CPC分类号: A61K9/1272 Y10T428/2984

    摘要: A liposome having a lipid bilayer, where the lipid bilayer includes either the L or D stereoisomer of an ether lipid or a non-equal mixture of both. Most preferably the liposome also comprises (a) an underivatized phosphatidylcholine; (b) a sterol; (c) about 5-20 mole % of a phosphatidylethanolamine linked to a dicarboxylic acid at the ethanolamine group of the phosphatidylethanolamine, and (d) greater than about 10 mole % to less than about 30 mole % of either the L or D stereoisomer of an ether lipid. The liposome may be used as an anti-cancer or anti-inflammatory agent.

    摘要翻译: 具有脂质双层的脂质体,其中脂质双层包括醚脂质的L或D立体异构体或两者的不相等的混合物。 最优选地,脂质体还包含(a)未衍生的磷脂酰胆碱; (b)固醇; (c)约5-20摩尔%的与磷脂酰乙醇胺的乙醇胺基上的二羧酸连接的磷脂酰乙醇胺,和(d)大于约10摩尔%至小于约30摩尔%的L或D立体异构体 醚类脂质。 脂质体可以用作抗癌剂或抗炎剂。